Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLNR | O43193 | 2/20 | 0.39 |
| ▸ | APP | P05067 | 3/20 | 0.39 |
| ▸ | RAF1 | P04049 | 3/20 | 0.37 |
| ▸ | MAP2K1 | Q02750 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.34 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4381860 | 0.85 | EGFR (0.40) | NPC1RAB9A | |
| SCHEMBL4392541 | 0.81 | MLNR (0.38) | MLNRKMT2ARAB9A | |
| SCHEMBL4383171 | 0.78 | PTGER1 (0.48) | NPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL4380278 | 0.77 | HPGD (0.42) | NPC1KDM4ELMNAHPGDRAB9A | |
| SCHEMBL4382835 | 0.74 | CYP4F2 (0.43) | NPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL4384794 | 0.73 | PLA2G2A (0.41) | NPC1KDM4EHPGDRAB9ASMN1; SMN2 | |
| SCHEMBL4381086 | 0.72 | ALDH1A1 (0.42) | MEN1LMNAKMT2ARAB9A | |
| SCHEMBL4381582 | 0.72 | LRRK2 (0.41) | NPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL4395202 | 0.70 | L3MBTL1 (0.42) | MEN1LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL4383989 | 0.70 | YAP1 (0.41) | MEN1LMNAKMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538241-B2 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-05-26 | — | — | US | disclosed |
| US-20070155813-A1 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-07-05 | — | — | US | disclosed |
| EP-1704856-A1 | HSP90 FAMILY PROTEIN INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-09-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155813-A1 | Hsp90 family protein inhibitors | HSP90AB1, HEATR1, HSP90AB2P | MLNR 846/4885APP 2244/4885RAF1 646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.